Contingent claim valuation

A discounted cash flow model values one future. It takes a forecast and discounts it.

But a business usually holds choices it has not made yet. It may build a second plant if demand grows. It may abandon a project if demand does not. It may wait a year before launching. Those choices have value, and a single forecast misses all of it.

The workbook calls such a choice an embedded real option. Contingent claim valuation is the approach that prices it: it uses option pricing models inside a cash flow based valuation, so the choice is valued rather than assumed away.

The name says the same thing. The extra value is contingent — it depends on what happens next.

This matters most for the companies a Category I or II AIF backs. A young company is often worth far more for what it may do than for what it is doing now.

The workbook's definition (Chapter 11, section 11.4). In the business valuation chart, under Other Approaches: contingent claim valuation uses option pricing models in cash flow based valuation to factor in embedded real options.

That is all XIX-D says about it. The workbook names no option pricing model for this approach, gives no formula, works no illustration and carries no figure. A candidate who writes a Black-Scholes calculation for this approach is going beyond this paper.

Where it sits among the five approaches. Section 11.4 sets out three families and five approaches, and then says the ones mainly used are the earnings approach based on DCF (the income approach), relative valuation based on earnings multiples (the market approach) and the asset based approach (the cost approach). Contingent claim valuation and the economic profit approach are the two listed but outside that trio.

Why the mainly used approaches miss an embedded option.

An embedded real option is entirely future value, and it is exactly what makes a business model unique. So all three of the usual approaches under-state it.

A separate mention of option pricing, which the workbook does not join to this approach. Section 11.8.3 lists the seven most widely used IPEV methods for valuing a portfolio company. The second — early-stage companies — says seed, start-up and early-stage investments are typically valued using a milestone approach or scenario analysis, because it is difficult to gauge the probability and financial impact of success or failure of development or research activity and to make reliable cash flow forecasts. It adds that the option pricing method (OPM) is also used sometimes: a forward-looking method that considers the current equity value and then allocates that value across the various classes of equity, assuming a continuous distribution of outcomes rather than distinct future scenarios.

Read that carefully. OPM allocates an already-determined equity value between share classes. Contingent claim valuation values an embedded operating choice inside a cash flow model. Both involve option mathematics, and XIX-D nowhere says they are the same thing. Keep them apart.

Illustrative. Section 11.4 gives no worked example and no figure for this approach, so every number below is an assumption. It is shown only to make the shape of the problem visible.

Suvarna Biosciences is a Category II AIF portfolio company. It has one approved product on the market and one molecule in trial.

Step 1 — the cash flow based value of what exists. Free cash flow of Rs 18 crore a year for 8 years, discounted at 16%, gives a present value of about Rs 78 crore. That is the whole of a plain income-approach answer.

Step 2 — the choice the forecast leaves out. The company holds a right, not an obligation. If the trial reads out well it can spend Rs 40 crore on a plant and enter a second market. If it reads out badly it spends nothing and walks away. The downside is capped at zero because the spend is optional — and that asymmetry is what an option is.

On these assumptions the choice is worth 0.30 × Rs 110 crore = Rs 33 crore, and none of it appears in the Rs 78 crore.

Step 3 — what a contingent claim valuation would do differently. It would price that choice with an option pricing model rather than with a two-outcome table, and add the result to the cash flow based value. The table above is closer to the scenario analysis that section 11.8.3 describes for early-stage companies than to an option pricing model, and XIX-D does not supply the model. So use the table to see why the approach exists, and do not present it as the approach itself.

Step 4 — the point, in one line. Rs 78 crore is not the answer when a real option is sitting inside the business. Whether the right answer is Rs 111 crore, or something an option model would put above or below it, XIX-D does not say.

Chapter 11, section 11.4 (Approaches to Business Valuation), and nothing else. The chart is a one-mark recall question waiting to be asked: which approach uses option pricing models in cash flow based valuation to factor in embedded real options? Contingent claim valuation.

The paired question is the negative one. The workbook says the approaches mainly used are the income or DCF approach, relative valuation and the asset based approach — so contingent claim valuation and the economic profit approach are the two on the chart that fall outside it.

Section 11.8.3 is where the option pricing method appears, under early-stage companies in the IPEV list, alongside the milestone approach and scenario analysis. Because both passages involve option pricing, a question that names OPM is testing 11.8.3 and not 11.4.

• Contingent claim valuation is not the option pricing method (OPM). OPM, in section 11.8.3, takes the current equity value and allocates it across classes of equity on a continuous distribution of outcomes. Contingent claim valuation puts an option model inside a cash flow valuation to value an embedded real option. XIX-D never equates them.
• No model, no formula, no figure. The workbook gives one sentence. If an answer option attaches Black-Scholes, a binomial tree or a volatility input to this approach, it is not from XIX-D — though Black-Scholes is taught in other NISM papers, so recognise the name without importing it here.
• A real option is not a traded option. It is a choice the business holds about its own operations — expand, delay, abandon — not a contract on a stock exchange. And it is not a residual put option either, which is a contractual exit right negotiated into a shareholders agreement.
• It belongs to the cash flow family, not the multiples family. The option pricing model goes inside a cash flow based valuation. It is not a market multiple.
• It is one of the five approaches on the chart but not one of the three mainly used. That is the discriminator between reading the chart and reading the paragraph under it.
• Scenario analysis and the milestone approach are the workbook's early-stage answers, in section 11.8.3, and they are not the same as an option pricing model. A probability-weighted table is scenario analysis.
• Asset based valuation cannot substitute. The workbook says it takes no account of any future value attributable to the business, and an embedded option is nothing but future value.